| A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants |
Completed |
Meningococcal ACWY Conjugate Vaccine |
3b |
V59P23 |
KFMC |
| A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) |
Ongoing |
Trastuzumab Deruxtecan |
3 |
D9670C00001 |
King Fahad Medical City (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
BMN 110 |
3 |
MOR-004 |
KFSH & RC-R |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2) |
Ongoing |
Voxelotor (GBT440) |
3 |
GBT440-032 |
King Khalid University Hospital (Riyadh) |
| A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes |
Completed |
ITCA 650 |
3 |
ITCA 650-CLP-105 |
NGHA-J |
| A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine. |
Completed |
13-valent Pneumoccocal Conjugate Vaccine |
3 |
B1851013 |
KFSH & RC-R |
| A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis” LUCENT 2 |
Ongoing |
Mirikizumab |
3 |
I6T-MC-AMBG |
KFSH-D |
| A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 1 |
Ongoing |
Mirikizumab |
3 |
I6T-MC-AMAN |
KFSH-D |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease |
Ongoing |
Ozanimod HCl |
3 |
RPC01-3203 |
KAUH-J |
| A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors |
Ongoing |
ABL001 (asciminib) |
3 |
CABL001A2301 |
KFSH&RC-R |
